C4 Therapeutics, Inc. (CCCC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
C4 Therapeutics, Inc. (CCCC) is listed on Nasdaq, where it has traded since October 2, 2020.
- Listed On
- Nasdaq
- Listed Since
- October 2, 2020
- Employees
- 104
- Market Cap
- $367M
About C4 Therapeutics, Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 144 institutions reported holding CCCC, with 117.6 million shares worth $547.6 million in aggregate. The largest reported holder was Morgan Stanley, with 8.9 million shares worth $41.4 million. Of the 5 largest holders listed below, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Morgan Stanley | 8,867,338 | $41M | Reduced 2.26% |
| RA Capital Management, | 8,000,000 | $37M | Unchanged |
| BlackRock | 7,896,718 | $37M | Added 285.48% |
| Lynx1 Capital Management | 7,326,691 | $34M | Added 4.68% |
| Squadron Capital Management | 7,200,000 | $34M | Added 220% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is CCCC?
C4 Therapeutics, Inc. (CCCC) is listed on Nasdaq, where it has traded since October 2, 2020.
Who are the largest institutional holders of CCCC?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of CCCC were Morgan Stanley, RA Capital Management, and BlackRock.
How many institutions own CCCC?
144 institutions reported a position in CCCC for the quarter ended June 30, 2026, worth $547.6 million in total.
Did institutions buy or sell CCCC last quarter?
Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for CCCC.
Every reported institutional holder, plus insider and congressional trades in CCCC, on SentiSense.